
THE LIBRARIANS: THE NEXT CHAPTER Recap: (S01E05) And the Memory Crystal
In The Librarians: The Next Chapter 's 'And the Memory Crystal,' the question of how much of who we are is because of who we've been is posed as a pseudo-academic, polymathic megalomaniac attempts to gain the future at the price of the past. Every team member's very existence depends on stopping the malefactor.
RELATED: Catch up with our recap of the previous episode of The Librarians: The Next Chapter , 'And the Thief of Love'
It's a real team-centered adventure. Like Charlie (Jessica Green) with her starry-eyed moment meeting Dame Anna (Arielle Dombasle) in The Librarians: The Next Chapter, 'And the Dance of Doom!' Lysa (Olivia Morris) goes a bit fangirl when she meets one of her heroes here. For those keeping score, so far this season, Connor (Bluey Robinson) has climbed on top of a moving ghost train and the Eiffel Tower. He gets to show off those skills again, while Charlie's in the crosshairs of the artifact's powers, and Vikram (Callum McGowan) gets to beat up a bad guy. Photograph by Aleksandar Letic The Librarians: The Next Chapter, 'And the Memory Crystal'
Lysa takes Vikram to the College of Science Observatory to get him up to speed on modern science. They attend Rosalind Kirch's (Ana Sofrenović) lecture. Kirch developed a hypothesis on interstellar dust and active galactic nuclei while sitting under a tree on campus, watching the oil droplets in her tea. Dr. Stanaris (Paul Leonard Murray) introduces Dr. Kirch.
RELATED: Olivia Morris Shares How The Librarians: The Next Chapter Hooked Her From Page One
Dr. Kirch takes the podium and begins to speak about developing her hypothesis on X-ray emission as a predictor of an accreting black hole system. Reminiscing about the moment under the tree, she suddenly stops speaking. Her eyes flicker with a blank light. She becomes confused, and Dr. Stanaris helps her off the stage. A Sharp Mind Dulled
Lysa and Vikram return to the Annex. Connor joins them. Lysa believes Dr. Kirch suffered a neuro-cognitive episode. Vikram thinks Kirch's memory loss is caused by a spell. Charlie comes in with the pendulum, having given it a tune-up. The pendulum flies out of her hand to the map table and indicates an event at the College of Science Observatory.
They review Lysa's recording of Dr. Kirch speaking. Using Lysa's AI-enhanced 3D program, they're able to zoom in and freeze on the moment her eyes go blank. Lysa grudgingly admits the magical event had something to do with Kirch's memory loss. When the team finds Dr. Kirch, she is solving a hitherto unsolvable integral problem.
RELATED: Read our Leverage: Redemption recaps
Kirch tells them the solution came to her in a flash the night before. Lysa asks Kirch about her episode at the lecture. Kirch tells her that the famous moment under the tree has completely vanished from her memory. In its place, she now has the solution to a Millennium Prize Problem no one thought would be solved for decades. The Value of Memories
After leaving Dr. Kirch, Vikram berates the younger team members, arguing that people in the modern world have stopped using their brains and hearts. As he finishes his tirade, a student walks by, describing how he couldn't remember how he got into the classroom, never mind what he needed to know to write the test. Vikram concludes the spell is spreading.
After questioning the students who have lost their memories, the common thread is that they have all been to the observatory recently. Vikram vows violent vengeance on the spell-caster(s). Charlie reminds him that their mission is to contain the magic, not beat up bad guys.
RELATED: TV Review: Leverage: Redemption Season 3
Vikram mistakenly addresses Lysa as Anya. He covers for the slip and quickly sends her and Connor to the Astronomy Department Office to suss out any artifacts. He and Charlie will try to figure out who is stealing the memories. Meeting the Suspects
In the Astronomy Department Office, Connor and Lysa meet Dr. Stanaris's teaching assistant, Filip (Vukašin Jovanović), while Vikram introduces himself to Dr. Stanaris in the observatory. Charlie shadows Vikram and quietly examines the observatory setting and telescope.
In the office, Lysa distracts Filip while Connor snoops in the back rooms. He finds an antique portfolio filled with papers and steals it. Connor finds Lysa having an unproductive conversation with a clearly uncomfortable Filip. Lysa gets Connor's hint that they should get going, and they leave quickly, to Filip's relief.
RELATED: On Location: The Belgrade Fortress on The Librarians: The Next Chapter
Outside, they meet up with Vikram and Charlie. Connor shows them the portfolio and explains that it contains documents kept by Nicholas Culpeper, a 17th-century artifact collector. Vikram connects Culpeper to the Crystal of Dr. John Dee. Photograph by Aleksandar Letic John Dee's Crystal
John Dee, Queen Elizabeth I's court magician, used his crystal to see the future, but eventually saw something that made him lose his mind and memory. Among the Culpeper Papers, Connor finds John Dee's own papers on the crystal, an instruction manual. They're written in High Enochian, a language Dee invented, which Vikram can read.
Back at the Annex, Vikram translates that the crystal is harmless when in its necklace setting. If taken out, it can grant a single, desired glimpse into the future in exchange for a memory. When the crystal is amplified to the point of clearing the past, the knowledge of the future is limitless. Some of Dee's papers are missing.
RELATED: Dean Devlin Dishes on The Librarians: The Next Chapter 's Magical Homecoming
Connor reports that the crystal and papers were stolen from the London Science Museum. Vikram leads the team back to the college, determined to confront Filip and Dr. Stanaris and force them to confess. Lysa and Charlie try to convince him that violence is the last resort. Suddenly, Lysa notices Filip in a very expensive car. Vikram sends Connor and Charlie to find Stanaris while he and Lysa question Filip. Suspicious Minds
When Vikrim confronts Filip, the teaching assistant tries to make a getaway, but Vikrim jumps into the back of the convertible. Filip's eyes flicker blank as he's driving at top speed. He's forgotten how to drive. They swerve and careen around campus roads and plazas nonstop, somehow avoiding crashing into people, buildings, and trees. Also, not slowing down.
Vikram calls Connor using his cell phone. Connor and Charlie run out of the observatory and spot Vikram and Filip on the plaza. Charlie grabs a bicycle and chases down Filip's car. Jumping into the passenger side, she pulls the emergency brake, bringing the car to a stop. She looks around, confused. When Connor and Lysa join them in the car, she doesn't know who they are.
RELATED: 5 Great Books About Libraries and Librarians
Vikram tries to remind Charlie of who they are and what they're doing, but she's lost the memory of Jacob Stone (Christian Kane) recalling her to be Vikram's Guardian. Elsewhere, Filip tells Lysa and Connor he bought the car with casino winnings after he had a vision of a roulette wheel. The Vault
Since Charlie's memory gap is bigger than Filip's, Vikram concludes the crystal's power is growing. Connor reports that Filip told them that Stanaris traveled to England the weekend the crystal disappeared from the Science Museum. Filip believes the crystal might be in the vault in the basement.
Charlie still doesn't trust the team. She suspects they are actually the Library's enemies, trying to corrupt her. Vikram sends the others on to the vault and briefs Charlie on everything she's done as part of their team in the past five weeks. In the basement, Lysa uses her AI-enhanced 3D program on her phone to enhance a still of Stanaris's face to fool the vault's retinal scan.
RELATED: 10 Out-of-This-World Predictions for Resident Alien Season 4
Lysa goes outside to bring Vikram and Charlie in. As they pass through the office space, a portrait of Dr. Kirch morphs into a man. In the vault, Vikram finds the case the crystal was stored in, but it's empty. Lysa runs in with a copy of Dr. Kirch's book, only the cover image and authorship have changed to a man named Dr. Laszlo Maisch. Remembering the crystal's instructions, they realize the crystal's effect is erasing past events, not just the memories of them. Dr. Stanaris's desire for limitless knowledge of the future is costing actual historical events. Vikram deems Stanaris a 'remorseless monomaniac.' Lysa translates that as a modern-day sociopath. Magical Causality
The team reasons that Stanaris must feed the crystal other people's memories to amplify its powers. Each time someone looks through the crystal, it takes more memories and grows in strength. Connor asks when Charlie would've looked through the crystal. Vikram remembers that she looked through the telescope when they visited Stanaris in the observatory. Filip and Dr. Kirch also looked through the telescope. The crystal must be in the telescope's viewer.
Dr. Stanaris suddenly appears at the vault door and locks them in. Lysa tries to appeal to his conscience, but he proudly declares that he doesn't care about the effects of his plan and expresses his rage and disdain for those who have undervalued his intellect.
RELATED: TV Review: Resident Alien Season 4
While they try to figure out a way to escape the vault, Lysa shares that erasing past events takes time to catch up to the present. So when Charlie's lost memory of joining the team catches up with the present, no one will save them from the drekavac (in The Librarians: The Next Chapter series premiere), and they'll be dead. Crystal Moments
In the observatory, a magical bubble forms around the telescope's viewer. In the vault, Connor recalls that museum security systems like the vault's have a fire override failsafe. Lysa finds the sensor in the ceiling. Connor hands her a lighter to trigger it, opening the vault door.
The magical bubble in the observatory grows to fill the room. Stanaris holds the necklace setting in his hand and steps inside. Connor and Lysa run into the bubble and immediately become confused. Charlie and Vikram reach through, pull them out, and drag them into a corridor. To get the crystal away from Stanaris, Vikram intends to enter the bubble himself, arguing that his mental discipline will protect him from the effects of the crystal.
RELATED: Revival : The Dead Have Rejoined the Living in Official Trailer
Vikram enters the bubble. Stanaris wonders how he can resist the crystal's effects. Vikram claims to be able to partition his memories from his active brain. He holds onto what he needs and gives away meaningless memories to the crystal's appetite for energy. It's still a struggle, though. He stumbles closer to Stanaris and the telescope's viewer. Stanaris suddenly asks what Vikram values most in the world. Involuntarily, Vikram thinks of Anya, and the crystal consumes his memory of her. An Upper Hand
Losing Anya breaks Vikram mentally, and he falls to the ground. Stanaris smiles in victory, asking Vikram innocently if he forgot something. Downstairs, in the mechanical room, Charlie shows Connor and Lysa that her hand is phasing out of existence. Connor runs outside and climbs to the top of the observatory.
In the bubble, Stanaris pulls out the John Dee papers he kept, which explain that wearing the crystal's necklace protects the wearer from the crystal's effects. Down in the mechanical room, Lysa holds Charlie as other parts of the Guardian's body begin to fade. She begs Charlie to fight the effects.
RELATED: Revival : Check Out 9 First-Look Photos From Melanie Scrofano-Led Series
Connor reaches the opening in the observatory's roof just as the crystal's bubble grows bigger than the observatory. Once engulfed, he forgets why he's up there and falls through, barely holding onto the ledge. Vikram looks up and sees Connor. This jolts his memory for a moment, and when Stanaris also sees Connor hanging from the observatory's opening, Vikram sneaks up and rips the necklace off him. Vikram throws the necklace to Connor. When Connor catches it, he remembers why he's there. He leaps onto the telescope and slides down it, breaking the viewer off and knocking the crystal loose. Photograph by Aleksandar Letic Magic Managed
Stanaris picks up the crystal with no idea what it is. Vikram knocks it out of his hand with his cane at Connor. On the backswing, he knocks Stanaris to the ground. Connor pops the crystal back into the necklace, and the bubble disappears. Running down to the mechanical room, Vikram and Connor are relieved to see Charlie whole and happy.
The next day, Lysa sits down with Dr. Kirch, who describes the sensation of disappearing, then remembering the moment when she developed her hypothesis. Lysa notes that Kirch has erased the solution to the Millennium Prize Puzzle equation. Kirch tells her she didn't trust the equation, not knowing how it popped into her head. 'Scientific advancement,' she tells Lysa, 'should come through replication of scientific method.'
RELATED: Read our recaps of The Librarians: The Next Chapter
Back at the Annex, the team debriefs on everyone affected by the crystal as Vikram packs it and John Dee's papers into a lockbox. Charlie reports she's feeling better. Vikram asks her what vision of the future she saw. She unconvincingly claims it disappeared once the crystal was contained.
Connor wonders where Stanaris ended up. In a white room, Stanaris lectures on the reverse amplified view of the universe, claiming it proves that the great minds of science added nothing to the world compared to him and his glimpse into the future. He rants that he'd still be viewing the future if it wasn't for those meddling Librarians.
New episodes of The Librarians: The Next Chapter air on TNT on Mondays at 9 pm ET.
REVIVAL: Co-Creators Aaron B. Koontz and Luke Boyce on Crafting 'Weird' New Series Diana lives in Vancouver, BC, Canada, where she invests her time and energy in teaching, writing, parenting, and indulging her love of all Trek and a myriad of other fandoms. She is a lifelong fan of smart sci-fi and fantasy media, an upstanding citizen of the United Federation of Planets, and a supporter of AFC Richmond 'til she dies. Her guilty pleasures include female-led procedurals, old-school sitcoms, and Bluey. She teaches, knits, and dreams big. You can also find her writing at The Televixen, Women at Warp, TV Fanatic, and TV Goodness.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
35 minutes ago
- Forbes
Where Art Breaks Free: Standout Installations At Art Basel's Unlimited 2025
Messe Basel Art Basel has opened its doors today for the preview days, ahead of the public opening on Thursday, 19 June 2025. One of its most compelling sectors is Unlimited - a space dedicated to ambitious, large-scale works that push beyond the confines of the traditional fair booth. Curated by Giovanni Carmine, it brings together monumental installations, immersive video works, expansive sculptures, and live performances in a setting designed for bold artistic expression. Below, a selection of my personal highlights from this year's edition: Marinella Senatore, We Rise by Lifting Others (2023) Presented by Mazzoleni The first work you see as you enter Unlimited, Marinella Senatore's illuminated sculpture sets the tone. Bold and bright, it draws on the tradition of Southern Italian festival lights - welcoming, communal, and full of presence. WE RISE BY LIFTING OTHERS Her message is simple but resonant. Senatore's work often begins with people: collective energy, shared authorship, and moments of coming together. Here, that spirit is made visible in light and language. A powerful opening gesture - uplifting in more ways than one. FEATURED | Frase ByForbes™ Unscramble The Anagram To Reveal The Phrase Pinpoint By Linkedin Guess The Category Queens By Linkedin Crown Each Region Crossclimb By Linkedin Unlock A Trivia Ladder Ayan Farah, Desert Seeds, 2025 Presented by Kadel Willborn (Düsseldorf) and Galerie Nordenhake (Berlin, Mexico City, Stockholm) in Unlimited Ayan Farah's Desert Seeds is a 12-meter-long wall piece dyed with clay from Somalia's Sanaag region, where her parents were born, and cloud-seeded water from the UAE, where she was born. Embroidered with images of extinct desert plants, the work unfolds as a quiet meditation on memory, migration, and belonging. Desert Seeds by Ayan Farah, 2025, Courtesy of Galerie Nordenhake and Kadel Willborn, photo by Simon ... More Vogel5 Farah's practice is rooted in movement - of people, materials, and meaning. Drawing from her Somali-Swedish heritage and nomadic upbringing, she collects natural pigments and vintage fabrics from across the globe, working with organic and earth-derived materials treated through slow, elemental processes of dyeing, bleaching, and exposure to light. Ayun Farah, Dessert Seeds, close up of embroidery Her work resists linear narratives. It brings together opposing forces: history and erosion, order and improvisation, nature and abstraction. In Desert Seeds, the earth becomes both medium and message, layered with time, intention, and the weight of personal and collective histories. Latifa Echakhch: Untitled (Tears Fall), 2025 Presented by PACE and kaufmann repetto, in collaboration with Dvir Gallery. Being shown for the first time at Unlimited, Latifa Echakhch's work forms a delicate, glimmering curtain of nylon threads, each tipped with glass spheres and strung with beads suspended at varying heights. The work evokes the moment water strikes a surface - frozen in both descent and ascent. Latifa Echakhch: Untitled (Tears Fall), 2025 Referencing the push and pull between sorrow and hope, Echakhch transforms water into a metaphor for emotional duality. In her view, beauty persists - even in collapse. In God We Trust, Danh Vo', 2020 Presented by White Cube Thirteen steel stars and a stack of firewood form the bones of Vo's quiet yet charged reflection on the American experiment. Based on the 1777 flag of the original 13 colonies, the work translates national symbolism into raw material. Stars are forged in metal, stripes are built from logs. "In God We Trust, 2020" Danh Vo First shown at White Cube in London during the lead-up to the 2020 U.S. election, the piece was dismantled over time, with the wood burned to heat the gallery's fireplaces. As the flag vanished, only stars and ash remained—an image of disintegration, or perhaps transformation. Vo's ongoing examination of empire and identity unfolds here as both monument and elegy. The work is as much about collapse as it is about the constant reshaping of political meaning. Nadira Husain, The Haunted Museum, 2025 Presented by PSM (Berlin) in collaboration with Hua International (Berlin, Beijing) Since the 1920s, the bust of the Egyptian Queen Nefertiti has drawn crowds to Berlin's Neues Museum. In The Haunted Museum, Nadira Husain offers a different vision: what if the queen had arrived in Germany today? Her freestanding wooden triptych shows Nefertiti not on a pedestal, but in everyday life - painted in bold colors, wearing Adidas tracksuits, navigating a new reality. Blending satire with historical critique, Husain reflects on the legacy of colonial-era acquisitions and asks what restitution might mean in a contemporary context. Nadira Husain, The Haunted Museum, 2025 / Presented by PSM (Berlin) in collaboration with Hua ... More International (Berlin, Beijing) Luiz Zerbini, Os Comedores de Terra (Earth Eaters), 2025 Presented jointly by Fortes D'Aloia & Gabriel (São Paulo) and Sikkema Jenkins & Co. (New York). A five-meter panoramic painting on a freestanding installation. On the reverse, mineral elements (crystals, stones, and ore) are embedded directly into the structure. Courtesy Fortes D'Aloia & Gabriel, São Paulo:Rio de Janeiro The work draws from images of gold mining in the Amazon, referencing extractive practices like logging and slash-and-burn farming. A rainbow film of gasoline shimmers across a pit of water; smoke rises among felled trees. Zerbini's intricate, layered composition immerses the viewer in a landscape both vibrant and violated. Courtesy Fortes D'Aloia & Gabriel, São Paulo:Rio de Janeiro As the artist notes, 'The laws that guide painting are similar to those that guide nature—they follow similar principles, such as coexistence, tension, triggers and understanding.' Lee Ufan, Relatum - Dialogue 2005/2023 presented by Lisson Gallery In the middle of the fair's energy, Lee Ufan's Relatum - Dialogue offers a rare moment of stillness. Heavy steel plates lie in quiet dialogue with raw stones - nothing forced, nothing decorative. Just material, presence, and space. Lee Ufan's Larger Than Life Installation at Art Basel's Unlimited Sector His works are never about spectacle. They ask you to pause, to consider weight, distance, and the invisible relationships between objects. It's part of a practice he's been developing for decades - deeply influenced by Mono-ha and shaped by both Korean and Japanese philosophies. There's a quiet kind of clarity in this installation. The kind that doesn't need explanation.
Yahoo
an hour ago
- Yahoo
ONWARD Medical Builds Commercial Momentum for the ARC-EX System and Reinforces its Brain-Computer Interface Leadership in Q1 2025
EINDHOVEN, the Netherlands, June 17, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces its Q1 2025 business update and year-to-date highlights: Commercial traction: Following FDA market authorization, the Company met its Q1 objective for the limited initial phase of its US launch of the ARC-EX® System, hiring, training and deploying a field organization, establishing a sales and service process, building a roster of reference clinics, and selling ten systems. Technology advancement: The Company's investigational ARC-IM® and ARC-BCI® platforms reached new milestones with the 4th and 5th successful BCI implants to restore thought-driven movement, and the first human implant of its investigational ARC-IM Lumbar Lead, which is designed to help restore mobility. Scientific leadership: Further expanding the body of clinical evidence supporting the ARC-EX System, Pathfinder2 study results published in Neuromodulation: Technology at Neural Interface showed that sustained access to ARC-EX Therapy can continue to drive functional improvements. Participants continued to make gains after one year of treatment. Financial highlights: The Company established a sponsored Level 1 American Depositary Receipt ("ADR") program to facilitate US investor trading and participation in its growth. "Our Q1 achievements reflect ONWARD's successful transition to a commercial organization that delivers breakthrough therapies to people with spinal cord injuries," said Dave Marver, Chief Executive Officer of ONWARD Medical. "The initial demand for our ARC-EX System and strong positive feedback we've received from users gives us confidence we can deliver against expectations in 2025.' Commercial traction ONWARD met its Q1 objective for the limited initial phase of its US launch of the ARC-EX System, hiring, training and deploying a field organization, establishing a sales and service process, building a roster of reference clinics, and selling ten systems. Strong early demand and positive feedback from users suggest the Company expects to meet its 1H sales target of approximately 30 systems and deliver a strong 2025. The Company also secured access to prominent US government online procurement platforms, enabling Veterans Affairs (VA) and other US government buyers to purchase the ARC-EX System. Technology advancement ARC-IM System In the first quarter, ONWARD announced the first human implant of its ARC-IM Lumbar Lead. The new lead is designed for placement in the lumbar region of the spinal cord, the optimal location for therapies targeting restoration of standing, stepping, and lower limb mobility. The Company's ARC-IM Thoracic Lead has been used in humans since early 2023. The Company also announced two new grants to support early clinical feasibility studies using its ARC-IM System to help people with Parkinson's disease. The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded the Company's research partner .NeuroRestore a USD 1M grant to explore how the ARC-IM System can address mobility challenges in Parkinson's disease. The US Department of Defense awarded a USD 1.5M grant to ONWARD and .NeuroRestore to support a clinical feasibility study to explore how the ARC-IM System can address blood pressure instability in Parkinson's disease. The Company continues to prepare for the initiation of Empower BP, a global pivotal study to assess the safety and efficacy of the ARC-IM System to address blood pressure instability after SCI. Commencement of the study is pending Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA). ARC-BCI System In June, ONWARD announced the 4th and 5th successful implants of its ARC-BCI technology in two additional individuals. These achievements further reinforce ONWARD's leadership in developing BCI-enabled movement solutions for people with SCI. Both procedures were performed at Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, under the direction of Jocelyne Bloch, MD, Chief of Neurosurgery. The Company's innovations with BCI technology were featured on CBS 60 Minutes with Anderson Cooper, one of the most respected and longest-running US news programs. The segment highlighted the experience of study participants who received this breakthrough therapy. A companion segment, 60 Minutes Overtime, highlighted the Company's other advancements in SCI and Parkinson's disease. Scientific leadership In the first quarter, ONWARD announced the publication of positive results from the investigator-sponsored Pathfinder2 Study in Neuromodulation: Technology at Neural Interface. This peer-reviewed publication details findings from a one-year trial demonstrating that ARC-EX Therapy combined with activity-based rehabilitation delivered significant functional improvements when administered to people with SCI in community-based rehabilitation centers. Participants experienced gains in upper body strength, trunk control, and balance at one year of treatment, indicating no plateau in therapeutic benefit1. Financial highlights As part of the phased launch of the ARC-EX System in the US, the Company reported EUR 0.4M in revenue. The quarter ended with net cash of EUR 50.5M, in line with expectations. Facilitating greater access for US investors, in April the Company established a sponsored Level 1 American Depositary Receipt ("ADR") program through the Bank of New York Mellon ("BNY"). The ADRs trade on the OTCQX® Best Market under the symbol: ONWRY. Outlook Strong early demand for the ARC-EX System and positive feedback from initial users suggest ONWARD expects to meet its 1H sales target of approximately 30 systems and deliver a strong 2025 in line with expectations. The Company anticipates FDA clearance to market the ARC-EX System for home use. It also anticipates CE Mark authorization so it can begin marketing the device in Europe. The Company further expects to commence its Empower BP global pivotal study for the ARC-IM System. It also plans additional implants of its ARC-IM System and ARC-BCI to explore additional indications in SCI and Parkinson's disease. Webcast details ONWARD will hold a webcast today at 2:00PM CET / 08:00AM EST, hosted by CEO Dave Marver. To join the session, please register using this link. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company's ARC-EX System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI). Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, visit and connect with us on LinkedIn. To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete this webform. For Media Inquiries: Sébastien Cros, VP communications media@ For Investor Inquiries: investors@ Disclaimer Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited. 1ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Other Investigational Products: All other ONWARD Medical devices and therapies including ARC-IM and ARC-BCI are investigational and not available for commercial use.
Yahoo
an hour ago
- Yahoo
Angle PLC - EACR 2025: Innovation in AR Expression Profiling
ANGLE presents new data at EACR 2025 Highlighting Innovation in Androgen Receptor EXPRESSION profiling Poster presentation highlights development of a novel CTC-based assay GUILDFORD, SURREY / / June 17, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the presentation of a poster at the European Association for Cancer Research (EACR) Congress, taking place in Lisbon, Portugal from 16-19 June 2025. The poster entitled 'Combined microfluidic isolation and immunofluorescence staining of circulating tumour cells for the assessment of Androgen Receptor expression in metastatic prostate cancer blood samples', is being presented during the Biomarkers in Tissue and Blood session on Tuesday 17 June 2025. This assay addresses a significant unmet need in prostate cancer. The androgen receptor (AR) plays a central role in driving disease growth and progression, and changes in AR can lead to resistance to current treatments and the development of advanced incurable disease known as metastatic castration-resistant prostate cancer (mCRPC). With at least 130 ongoing clinical studies and a projected AR inhibitor market value of US $9.8 billion by 2032, there is growing demand for assays that can monitor AR activity1. ANGLE has developed a new approach for repeatable assessment of AR expression in prostate cancer patients using the Parsortix system and ANGLE's AR immunofluorescence assay. The assay was tested on blood spiked with prostate cancer cells exposed to increasing AR drug concentrations. The results showed a clear, statistically significant reduction in AR expression as AR-drug concentration increased, from over 80% AR-positive cells in untreated samples to under 20% at the highest drug level. This demonstrates the assay's high sensitivity and highlights its potential utility for pharmacodynamic assessment, enabling customers to monitor treatment response in real-time. The assay was then validated in blood samples from 20 patients with mCRPC. 50% of patients were CTC-positive and all CTC-positive patients had AR-positive CTCs enabling the assessment of AR expression levels. CTC clusters, which are known to be up to 100 times more metastatic, were observed in 80% of CTC-positive patients. All CTCs detected were mesenchymal or undergoing EMT, highlighting the importance of using the marker-independent Parsortix system in this patient cohort. This work demonstrates how ANGLE's Portrait AR workflow enables sensitive, real-time monitoring of AR expression from a simple blood draw. The assay is now available as part of ANGLE's assay menu to support pharma customers with longitudinal biomarker assessment in AR-targeted clinical trials. The poster will be available on ANGLE's website from 20:00 on Tuesday 17 June: ANGLE Chief Scientific Officer, Karen Miller, commented:"This work underscores the value of ANGLE's Parsortix system for enabling detailed protein analysis directly in intact CTCs. The androgen receptor assay development programme has successfully been completed, and we are excited by its potential to repeatably monitor drug response and resistance in prostate cancer trials. Sharing this data at EACR reflects our ongoing commitment to advancing precision oncology with innovative, real-world solutions." 1. For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Research Use Only. Not for use in diagnostic procedures. For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product: The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: ANGLE plc View the original press release on ACCESS Newswire Sign in to access your portfolio